Top 10 Oncology Capital Raises in the U.S. – November 16th-30th, 2024
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
1. Exicure, a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss, received $1.3 million of development capital from Hitron Systems through a private placement.
Buyout/LBO
2. ALZET Osmotic Pumps, manufacturer of infusion pumps and related accessories designed for universities and research institutions, was acquired by Lafayette Instrument Company, via its financial sponsor Branford Castle Partners, through an LBO.
Later Stage VC
3. Gliknik, operator of a biopharmaceutical company intended to treat cancer and autoimmune diseases, raised $11.17 million of venture funding in the form of convertible debt.
4. Strand Therapeutics, provider of biotechnology services intended to create gene therapies powered by synthetic biology, raised a venture funding from JIC Venture Growth Investments.
5. Strata Oncology, operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer, raised $6.15 million of venture funding i the form of convertible debt.
Early Stage VC
6. OncoVerity, operator of a biotechnology firm intended to develop targeted therapies for cancer, raised an undisclosed amount of Series A venture funding in a deal led by Argenx and RefinedScience.
Angel, Seed, and Grant
7. ARIZ Precision Medicine, developer a precision medicine platform designed to develop drugs that will get to the right place at the right time, raised $110,000 of angel funding.
8. NXgenPort, developer of a digital health technology designed to maximize remote care for cancer patients, raised a seed funding from CANCER FUND.
-
- Valora Therapeutics, operator of a pre-clinical stage biopharmaceutical company, raised $29.97 million of Seed funding in a deal led by Avalon Bioventures, Bregua Corporation and TigerGene.
- OverT Bio, operator of a biotech company intended to provide cell therapy for cancers, received $120,000 of grant funding from ScaleReady.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.










